Atossa Therapeutics (NASDAQ:ATOS) Given New $6.25 Price Target at Ascendiant Capital Markets

Atossa Therapeutics (NASDAQ:ATOS) had its target price hoisted by Ascendiant Capital Markets from $6.00 to $6.25 in a research report sent to investors on Thursday morning, Marketbeat reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an overweight rating on shares of Atossa Therapeutics in a research report on Tuesday, May 14th. StockNews.com upgraded shares of Atossa Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 14th. Finally, HC Wainwright boosted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the stock a buy rating in a research report on Monday, May 13th.

Atossa Therapeutics Stock Performance

ATOS stock opened at $1.25 on Thursday. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31. The company’s fifty day moving average price is $1.56 and its 200-day moving average price is $1.19. The company has a market capitalization of $157.20 million, a PE ratio of -5.21 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, May 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, research analysts predict that Atossa Therapeutics will post -0.23 EPS for the current fiscal year.

Insider Buying and Selling at Atossa Therapeutics

In other news, Director Jonathan Finn acquired 25,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were acquired at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATOS. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Atossa Therapeutics during the third quarter valued at $98,000. PFG Investments LLC purchased a new stake in shares of Atossa Therapeutics during the first quarter valued at $43,000. Vanguard Group Inc. boosted its stake in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the period. Virtu Financial LLC purchased a new stake in shares of Atossa Therapeutics during the first quarter valued at $151,000. Finally, Cetera Advisors LLC purchased a new stake in shares of Atossa Therapeutics during the first quarter valued at $72,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.